Thursday 7 May, 2026
Introduction: Niclosamide has demonstrated potent broad-spectrum antiviral activity against respiratory viruses, including SARS-CoV-2 and influenza [1, 2], but exhibits poor…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Mechanistically informed framework for selection of BBB permeability parameters in PBPK CNS modelling of passively diffusing compounds
Thursday 7 May, 2026
Introduction and Objective: Pharmacological effects are driven by drug concentrations at the target site. However, direct measurement of tissue fluid…
Read moreIMPACT OF CYP3A4 ONTOGENY ON PREDICTION OF DRUG CLEARANCE IN YOUNG PAEDIATRIC PATIENTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING
Thursday 7 May, 2026
Introduction: PBPK models account for developmental differences in physiology and pathology and thereby support precision dosing in paediatric populations. However,…
Read morePHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF ELEXACAFTOR–TEZACAFTOR–IVACAFTOR DURING PREGNANCY WITH INTEGRATED EX VIVO HUMAN PLACENTAL TRANSFER DATA TO PREDICT MATERNAL AND FETAL EXPOSURE
Thursday 7 May, 2026
Objectives: Pregnancies among women with cystic fibrosis (CF) have increased markedly in the era of highly effective CFTR modulators, particularly…
Read moreTHE CRITICAL ROLE OF GASTRIC REACIDIFICATION IN PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS INVESTIGATING FOOD EFFECT: A CASE STUDY WITH PICTILISIB
Thursday 7 May, 2026
Introduction Gastrointestinal tract physiology is influenced by prandial state, with characteristic differences in gastric pH, gastric emptying time, bile salt…
Read moreUSING PBPK MODELLING TO IDENTIFY PHYSIOLOGICAL CHANGES INDUCED BY CLF065, A GLP 2 RECEPTOR AGONIST, ON THE PHARMACOKINETICS OF ACYCLOVIR AND TO PREDICT POTENTIAL DRUG–DRUG INTERACTIONS WITH OTHER COMPOUNDS
Thursday 7 May, 2026
Introduction: CLF065 is a long-acting glucagon-like peptide 2 (GLP 2) receptor agonist in development by Calibr–Skaggs for the treatment of…
Read morePK-DB 2.0: An Open Pharmacokinetics and Pharmacodynamics Database for Pharmacometric Modeling, AI, and Digital Twins
Thursday 7 May, 2026
Introduction: The rapid growth of published pharmacokinetics (PK) and pharmacodynamics (PD) data from clinical and preclinical studies requires structured, interoperable,…
Read moreFood effect prediction of high permeability/low solubility compound, formulated as an amorphous solid dispersion (ASD) using an Open Systems Pharmacology (OSP) PBBM approach
Thursday 7 May, 2026
Introduction: Model-Informed Drug Development (MIDD) approaches are increasingly encouraged by regulatory agencies and adopted across the pharmaceutical industry to streamline…
Read morePRECLINICAL PBPK MODELING FOR PERSONALIZED THERAPY AND DOTA-TATE-BASED RADIOPHARMACEUTICAL MODULARITY
Thursday 7 May, 2026
Objective. Peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-DOTA-TATE is an established treatment for somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumours,…
Read moreDISEASE-INFORMED PBPK MODELLING OF RIFAMPICIN: MECHANISTIC INTEGRATION OF BILE SALT–MEDIATED DISSOLUTION TO PREDICT PHARMACOKINETIC VARIABILITY IN HEPATOBILIARY CONDITIONS
Thursday 7 May, 2026
Objectives Rifampicin is a BCS Class II antibiotic whose absorption is governed by solubility-limited dissolution regulated by bile salt–associated micellar…
Read more